Adding venetoclax to treatment with ibrutinib improved outcomes in patients with relapsed or refractory MCL in a phase 3 trial.

Researchers investigated the feasibility of using a wearable device to monitor patients with RRMM for CRS after undergoing CAR-T therapy, compared with standard-of-care nurse-recorded monitoring.

This study aimed to compare treatment patterns, efficacy, and safety of 2 frontline regimens in a large cohort of patients with newly diagnosed mutant IDH1 AML.

A cross-sectional survey of patients identified which social determinants of health domains contribute to delays in accessing care among patients with hematologic cancers.

A pilot project at a Philadelphia cancer center sought to improve awareness of financial assistance resources for patients with multiple myeloma.

An analysis of more than 2500 patients with low-risk MDS highlighted the benefits of iron chelation to reduce transfusion-related iron overload.

Researchers explored the efficacy of palliative care in the in-patient setting for patients with hematologic malignancies hospitalized for HSCT.

Olverembatinib improved event-free survival over best available therapy in patients with TKI-resistant chronic phase CML in a phase 2 trial.

Researchers sought to determine whether obinutuzumab administered after HSCT would lead to lower rates of GVHD.

An investigation of patients undergoing CAR-T therapy found neurocognitive outcomes decline in the first month after therapy, then patients are likely to recoup neurocognitive function by 3 months.